356 related articles for article (PubMed ID: 33535731)
1. Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma.
Peng YY; Xiong YY; Zhang LX; Wang J; Zhang HB; Xiao Q; Guo SL
Turk J Haematol; 2021 Jun; 38(2):126-137. PubMed ID: 33535731
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type.
Ennishi D; Maeda Y; Fujii N; Kondo E; Shinagawa K; Ikeda K; Ichimura K; Yoshino T; Tanimoto M
Leuk Lymphoma; 2011 Jul; 52(7):1255-61. PubMed ID: 21599584
[TBL] [Abstract][Full Text] [Related]
3. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
5. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
[TBL] [Abstract][Full Text] [Related]
6. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine.
Yuan L; Sun L; Bo J; Zhou Y; Li HH; Yu L; Gao CJ
Ann Transplant; 2011; 16(3):135-8. PubMed ID: 21959522
[TBL] [Abstract][Full Text] [Related]
7. Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
Weiner DM; Lewis DJ; Spaccarelli NG; Clark RA; Nasta SD; Loren AW; Rook AH; Kim EJ
Dermatol Ther; 2022 Jul; 35(7):e15538. PubMed ID: 35477952
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies.
Kwong YL
Bone Marrow Transplant; 2009 Dec; 44(11):709-14. PubMed ID: 19767784
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
Yokoyama H; Yamamoto J; Tohmiya Y; Yamada MF; Ohguchi H; Ohnishi Y; Okitsu Y; Fukuhara N; Ohba-Ohtsuka R; Kohata K; Ishizawa K; Kameoka J; Harigae H
Leuk Lymphoma; 2010 Aug; 51(8):1509-12. PubMed ID: 20496989
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.
Lee CH; Lin TC; Yao M; Hsiao LT; Ko BS; Liu CJ; Chen TY
Cancer Med; 2023 Dec; 12(24):21761-21769. PubMed ID: 38018321
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma.
Li M; Gao C; Li H; Wang Z; Cao Y; Huang W; Li X; Wang S; Yu L; Da W
Med Oncol; 2011 Sep; 28(3):840-5. PubMed ID: 20414818
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
Murashige N; Kami M; Kishi Y; Kim SW; Takeuchi M; Matsue K; Kanda Y; Hirokawa M; Kawabata Y; Matsumura T; Kusumi E; Hirabayashi N; Nagafuji K; Suzuki R; Takeuchi K; Oshimi K
Br J Haematol; 2005 Aug; 130(4):561-7. PubMed ID: 16098071
[TBL] [Abstract][Full Text] [Related]
15. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma.
Cudillo L; Cerretti R; Picardi A; Mariotti B; De Angelis G; Cantonetti M; Postorino M; Ceresoli E; De Santis G; Nasso D; Pisani F; Scala E; Di Piazza F; Lanti A;
Ann Hematol; 2018 Jun; 97(6):1041-1048. PubMed ID: 29442161
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
18. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Philippe Walter L; Couronné L; Jais JP; Nguyen PD; Blaise D; Pigneux A; Socié G; Thieblemont C; Bachy E; Fegueux N; Chevallier P; Mohty M; Yakoub-Agha I; Peffault de Latour R; Jaccard A; Hermine O;
Am J Hematol; 2021 Jul; 96(7):834-845. PubMed ID: 33864708
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
20. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.
Goldberg JD; Linker A; Kuk D; Ratan R; Jurcic J; Barker JN; Castro-Malaspina H; Giralt S; Hsu K; Jakubowski AA; Jenq R; Koehne G; Papadopoulos EB; van den Brink MR; Young JW; Boulad F; Kernan NA; O'Reilly RJ; Prockop SE; Yahalom J; Heller G; Perales MA
Biol Blood Marrow Transplant; 2013 Feb; 19(2):208-13. PubMed ID: 22982534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
